Edition:
India

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

44.30SEK
19 Jan 2018
Change (% chg)

1.10kr (+2.55%)
Prev Close
43.20kr
Open
43.15kr
Day's High
44.75kr
Day's Low
43.15kr
Volume
35,778
Avg. Vol
73,978
52-wk High
92.00kr
52-wk Low
43.05kr

Latest Key Developments (Source: Significant Developments)

Medivir: successful completion of pre-clinical safety studies with MIV-818
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Medivir ::SUCCESSFUL COMPLETION OF PRE-CLINICAL SAFETY STUDIES WITH MIV-818, ENABLING START OF PHASE I CLINICAL STUDIES IN 2018.  Full Article

Medivir proposes directed share issue, calls EGM
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Medivir ::THE MEDIVIR BOARD IS SEEKING ISSUE AUTHORIZATIONS TO INCREASE THE COMPANY'S FUNDING FLEXIBILITY AND CALLS FOR AN EXTRAORDINARY GENERAL MEETING.SAYS NOTICE FOR AN EXTRAORDINARY GENERAL MEETING, TO BE HELD ON 26 JANUARY 2018.SAYS ‍PROPOSAL FOR MEETING TO AUTHORIZE BOARD OF DIRECTORS TO RESOLVE ON A DIRECTED SHARE ISSUE OF NOT MORE THAN 20 PERCENT OF NUMBER OF SHARES OF SERIES B​.SAYS ‍IN ADDITION, BOARD PROPOSES THAT MEETING RESOLVES TO AUTHORIZE BOARD OF DIRECTORS TO ISSUE NEW SHARES OF SERIES B WITH PRE-EMPTIVE RIGHTS FOR COMPANY'S SHAREHOLDERS​.SAYS ‍HOLDERS OF MEDIVIR'S SERIES A SHARES HAVE NOTIFIED MEDIVIR THAT THEY ARE POSITIVE TO BOARD OF DIRECTORS' PROPOSALS​.SAYS ‍HOLDERS OF MEDIVIR'S SERIES A SHARES HAVE ALSO DECLARED THAT THEY WILL CONVERT THEIR SERIES A SHARES IN MEDIVIR TO SERIES B SHARES​.SAYS ‍IN ORDER TO ADVANCE MORE RAPIDLY DEVELOPMENT OF COMPANY'S CLINICAL PORTFOLIO, WISHES TO FURTHER INCREASE ITS FLEXIBILITY​.  Full Article

Medivir says Janssen to terminate Simeprevir license by June 2018
Sunday, 10 Dec 2017 

Dec 10 (Reuters) - Medivir Ab ::MEDIVIR ANNOUNCES JANSSEN DECISION TO TERMINATE ITS SIMEPREVIR LICENSE EFFECTIVE JUNE 2018.SAYS JANSSEN PHARMACEUTICALS INC. HAS DECIDED TO TERMINATE THE LICENSE THAT IT HOLDS FOR SIMEPREVIR DUE TO JANSSEN'S ASSESSMENT OF MARKET DEMAND.  Full Article

Medivir announces new cancer project
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Medivir Ab :Medivir announces new cancer project, Leukotide, derived from its in-house nucleotide platform.Says Leukotide project is intended to deliver a new drug for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.Says aim of the Leukotide project is to develop a better tolerated and more effective agent that can lead to improved treatment outcomes for patients with AML and other hematological cancers.  Full Article

Medivir Q3 EBITDA loss widens
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Medivir :Says ‍net turnover for continuing operations totalled SEK 5.1 million (25.7 m), SEK 5.1 million (13.5 m) of which comprised Q3's royalties​.Q3 ‍loss before interest, tax, depreciation and amortisation (EBITDA) totalled SEK -78.3 million (-53.9 m)​.  Full Article

Medivir receives FDA fast track designation for MIV-711 for treatment of OA
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Medivir :Medivir receives FDA fast track designation for MIV-711 for the treatment of OA.  Full Article

Medivir reports positive data in remetinostat phase II trial ‍​
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Medivir Ab :Medivir says ‍remetinostat phase ii data demonstrate efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage mf-type ctcl​.phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the severity of CTCL skin lesions.  Full Article

Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Medivir :Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C.Says ongoing phase ii studies with JNJ-4178 will continue as planned, but there will be no additional development thereafter..Says discontinuation of development of JNJ-4178 does not affect ongoing partnership with Janssen on Olysio (simeprevir), or existing licensing agreement with Janssen in which simeprevir is included.  Full Article

Medivir says names Christine Lind as new CEO
Thursday, 9 Feb 2017 

Medivir AB :Says Christine Lind new ceo of medivir ab effective 1 april 2017.  Full Article

Medivir says fusion inhibitor MIV-323 enters non-clinical development
Wednesday, 14 Dec 2016 

Medivir AB :Medivir's fusion inhibitor for the treatment of respiratory syncytial virus infection, MIV-323, enters non-clinical development.  Full Article

BRIEF-Medivir: successful completion of pre-clinical safety studies with MIV-818

* SUCCESSFUL COMPLETION OF PRE-CLINICAL SAFETY STUDIES WITH MIV-818, ENABLING START OF PHASE I CLINICAL STUDIES IN 2018 Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)